Update: Partner for Glucose Breath Test? |
 |
 |
| By Peter DePalma |
| Tuesday, 04 May 2010 09:05 |
 PositiveID Corporation (Nasdaq: PSID) is developing the non-invasive Easy Check breath glucose analysis system and sources are telling BioMedReports that a bigger company or two have taken an interest in partnering with them for a piece of the huge diabetic market that the test would open up.
As reported earlier, this unique, non-invasive glucose detection system measures the levels of acetone in a patient’s exhaled breath.It combines a proprietary chemical mixture with exhaled breath, which creates a new molecular compound that can be measured with the Company’s patent-pending technology. Industry sources say a significant partnership may be very close to completion and public announcement. Such news would not only help validate the technology, but would also likely send PSID's tightly floated shares upward. In the U.S. alone, 23.6 million people (7.8% of the total population) have diabetes. The PSID device could eliminate a patient’s need to prick his or her finger multiple times per day to get a blood sugar reading. Disclosure: Long PSID BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
about 3 hours ago
Medgenics ($MDGN) up 10% on Monday! We first told you about the firm last Friday: http://t.co/aD50CMSH
about 3 hours ago
Thinly traded BioLineRx shares move on hepatitis C deal: The shares of thinly traded BioLineRx (NASDAQ:BLRX) soa... http://t.co/ugbuZgNN
about 8 hours ago
Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment; Acorda Announces Launch of Generic ... http://t.co/vSt6VrLP
about 12 hours ago
$CVM up 17% and technically looks like it may head higher.
about 18 hours ago
$ANAC drops after GlaxoSmithKline (GSK) pauses enrollment for its clinical trials of its urinary tract infection drug. http://t.co/yUUSzkUr
about 18 hours ago
Catalysts on tap for Corcept: Corcept Therapeutics (NASDAQ:CORT) is a drug discovery company focused on the deve... http://t.co/jd3C1ddH
about 19 hours ago
Commented on: "Will Celsion's Upcoming Catalysts Help The Price Break-Out Stick?" http://t.co/dJ0reUFR $BSX $PHG $MDSO $CLSN
about 19 hours ago
Monday morning watch -- European Leaders Maintain Pressure on Greece to Complete Terms for Bailout - http://t.co/0wipY6QB via @BloombergNews
Free Phone Trade Alerts
